Medicine
Lifyorli kit
Lifyorli kit is a prescription medicine containing Relacorilant for oral use, marketed by Corcept Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store LIFYORLI at 20°C to 25°C (68°F to 77°F), excursions are permitted from…
Key facts
- Active ingredient (INN)
- Relacorilant
- Brand
- Lifyorli
- Dosage form
- Kit
- Route
- Oral
- Packs
- 1 blister pack, 3 cartons and 3 more
- Marketing authorisation holder
- Corcept Therapeutics
- Manufacturer
- Corcept Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store LIFYORLI at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F). Store and dispense LIFYORLI in their original carton.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 March 2026
- Identifiers
- RxCUI 2739542, 2739548, 2739550 +7DailyMed set ID 6fcebfb5-19d6-4f63-b852-999d68a13729NDC 76346-425, 76346-525, 76346-450 +1Application NDA220641
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-425-01 | Corcept Therapeutics | 25 March 2026 |
| 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-450-01 | Corcept Therapeutics | 25 March 2026 |
| 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-525-03 | Corcept Therapeutics | 25 March 2026 |
| 3 carton in 1 carton / 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-525-09 | Corcept Therapeutics | 25 March 2026 |
| 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-550-03 | Corcept Therapeutics | 25 March 2026 |
| 3 carton in 1 carton / 1 blister pack in 1 carton / 1 kit in 1 blister pack * 1 capsule in 1 package, combination * 1 capsule in 1 package, combination | 76346-550-09 | Corcept Therapeutics | 25 March 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 March 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Relacorilant is a prescription medicine indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. MedsAcross supplies Relacorilant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RelacorilantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lifyorli prescribing information (Corcept Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Lifyorli kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.